$113.98 -$0.15 (-0.1%)

04:00 PM EST on 12/10/19

Seattle Genetics, Inc. (NASDAQ:SGEN)

CAPS Rating: 3 out of 5

A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.

Current Price $113.98 Mkt Cap $19.6B
Open $114.00 P/E Ratio 0.00
Prev. Close $114.13 Div. (Yield) $0.00 (0.0%)
Daily Range $113.05 - $114.67 Volume 1,392,271
52-Wk Range $54.30 - $122.36 Avg. Daily Vol. 1,160,665

Caps

How do you think NASDAQ:SGEN will perform against the market?

Add Stock to CAPS Watchlist

All Players

452 Outperform
32 Underperform
 

All-Star Players

100 Outperform
11 Underperform
 

Wall Street

6 Outperform
2 Underperform
 

Top NASDAQ:SGEN Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

LifeScientist (34.19)
Submitted March 02, 2016

good dream for sales and appreciation

PDTBiotech (80.17)
Submitted July 07, 2011

$2.34B for a drug which treats HL and ALCL seems very, very rich, even when taking SGEN's strong balance sheet into account. Very cool platform, but the target for brentuximab vedotin is expressed on a narrow enough set of tumor types to keep this… More

Recent Community Commentary

Read the most recent pitches from players about SGEN.

Recs

0
Member Avatar TMFBiologyFool (70.57) Submitted: 10/2/2019 1:46:46 PM : Outperform Start Price: $84.58 NASDAQ:SGEN Score: +25.72

Multiple drugs in late-stage development.

Recs

0
Member Avatar SmoothHughes (92.70) Submitted: 11/17/2018 8:51:07 AM : Outperform Start Price: $56.99 NASDAQ:SGEN Score: +85.22

Technology replaces a 40 year old protocol for fighting certain blood cancers.

Recs

0
Member Avatar Bigsef77 (70.28) Submitted: 10/1/2018 2:51:48 PM : Outperform Start Price: $13.06 NASDAQ:SGEN Score: +600.49

Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline CD30-Expressing Peripheral T-Cell Lymphoma
Business Wire Business Wire•October 1, 2018

Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline CD30-Expressing Peripheral T-Cell Lymphoma
More
BOTHELL, Wash. & CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--

-ADCETRIS in Combination with Chemotherapy Achieved Primary Endpoint, Demonstrating a Statistically Significant Improvement in Progression-Free Survival Compared to a Standard of Care Chemotherapy-

-Statistically Significant Improvement Achieved in All Key Secondary Endpoints, Including Overall Survival-

-First Randomized Phase 3 Trial to Show Improvement in Overall Survival in Frontline Peripheral T-Cell Lymphoma-

-Data to be Presented at the 2018 ASH Annual Meeting; Global Regulatory Submissions Planned-

Seattle Genetics, Inc. (SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint. The trial demonstrated a statistically significant improvement in progression-free survival (PFS) of ADCETRIS (brentuximab vedotin) in combination with CHP (cyclophosphamide, doxorubicin, prednisone) versus the control arm, CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). ECHELON-2 is a global, randomized, double-blind, multicenter trial evaluating ADCETRIS as part of a frontline combination chemotherapy regimen in patients with previously untreated CD30-expressing peripheral T-cell lymphoma (PTCL), also known as mature T-cell lymphoma (MTCL). ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed on the surface of several types of PTCL. ADCETRIS is currently not approved for the frontline treatment of PTCL.

Leaderboard

Find the members with the highest scoring picks in SGEN.

Score Leader

lloydvon

lloydvon (< 20) Score: +2,288.89

The Score Leader is the player with the highest score across all their picks in SGEN.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
lloydvon < 20 8/30/2006 Outperform 1Y $4.48 +2,444.20% +155.31% +2,288.89 1 Comment
Zipsdad < 20 10/4/2006 Outperform 1Y $4.67 +2,340.69% +150.17% +2,190.52 0 Comment
twildstar 95.59 10/11/2006 7/20/2012 Outperform NS $4.93 +2,211.97% +145.27% +2,066.69 0 Comment
vkowalczuk 71.16 10/19/2006 Outperform 1Y $5.10 +2,134.90% +143.98% +1,990.92 1 Comment
RAIDERFAN77 70.77 1/3/2007 7/1/2009 Outperform 1Y $5.27 +2,062.81% +133.85% +1,928.95 0 Comment
SloopJohnB06 60.63 12/26/2006 Outperform 5Y $5.63 +1,924.51% +136.24% +1,788.27 0 Comment
muae1 < 20 12/18/2006 Outperform NS $5.76 +1,878.82% +133.37% +1,745.45 0 Comment
biogirl < 20 1/8/2007 Outperform 3M $6.45 +1,667.41% +136.47% +1,530.93 0 Comment
opveiby 77.93 1/8/2007 Outperform 1Y $6.46 +1,664.40% +136.42% +1,527.98 0 Comment
Turkmenbashi 52.50 1/8/2007 Outperform 3Y $6.59 +1,629.59% +135.66% +1,493.93 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for SGEN.